Novo Nordisk AS: 1 director

A director at Novo Nordisk AS bought 6,450 shares at 312.500DKK and the significance rating of the trade was 78/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...

Unwarranted sell-off

Beat in all segments, '25 guidance up

We are willing to accept noise

A solid start to the school year

A decent container market in a depressed world

Solid start, political shadows

Solid end to '24/'25, with operational optimism

Still cheap and more SBB underway

Exactly what the bulls wanted

Good risk/reward into the Q2 report

ABGSC Shipping Daily 16 July

Politics puts us on the sidelines

Continues its international expansion

Still cheap and the Red Sea is still closed

Genco Shipping & Trading Minor model adjustments

We have updated our estimates for the company’s Q1 results and other minor model adjustments. Hence, we have raised our 2025–2026e EBITDA by 1%, while we lowered our 2027e by 1%. We maintain that Genco’s steep discount to underlying values (0.57x EV/GAV) more than offsets the downside risk to our muted near-term outlook for the dry bulk segment and the entailing risk of negative momentum in asset valuations. Further, the company demonstrated an ability to adjust its quarterly reserve to facilita...

A. P. Møller Mærsk (Sell, TP: DKK9400.00) - Resistance to gravity seem...

The Q1 report was largely as expected, albeit with support in the results related to mostly passing effects. Hence, we retain our view that the chronic oversupply of vessels will deteriorate the current value of the company. On rates converging towards 2016 levels, it should burn through more than USD13bn by the end of our forecast period, with no respite in sight due to the towering orderbook and owners still willing to order. We reiterate our SELL, but have raised our target price to DKK9,400 ...

Zealand Pharma (Buy, TP: DKK950.00) - Dapiglutide likely next catalyst

Q1 revenue missed expectations on lower reimbursement revenue, while operating profit was a beat, as opex was below our forecast and consensus. The 2025 guidance was maintained for opex of DKK2,000m–2,500m. We believe the next potential share-price catalyst is the top-line results from the phase Ib dapiglutide trial in Q2e. We reiterate our BUY, but have cut our target price to DKK950 (1,000).

Meets expectations in Q3

Q1'25 beat driven by Ocean and Terminals